The primacy of public health considerations in defining poor quality medicines
about
Interventions to combat or prevent drug counterfeiting: a systematic reviewStrategies and Systems-Level Interventions to Combat or Prevent Drug Counterfeiting: A Systematic Review of Evidence Beyond EffectivenessA poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appealA tiered analytical approach for investigating poor quality emergency contraceptivesQuality of antimalarial drugs and antibiotics in Papua New Guinea: a survey of the health facility supply chainTechnologies for detecting falsified and substandard drugs in low and middle-income countries.Evaluation of a new handheld instrument for the detection of counterfeit artesunate by visual fluorescence comparisonQuality of artemisinin-based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu, NigeriaAssessing the quality of anti-malarial drugs from Gabonese pharmacies using the MiniLab®: a field studyThe global pandemic of falsified medicines: laboratory and field innovations and policy perspectives.Mind the gaps--the epidemiology of poor-quality anti-malarials in the malarious world--analysis of the WorldWide Antimalarial Resistance Network database.The need to look at antibiotic resistance from a health systems perspective.Quality assurance of medicines supplied to low-income and middle-income countries: poor products in shiny boxes?Poor-quality medicines: from knowledge to control and prevention.Accessibility and potency of uterotonic drugs purchased by simulated clients in four districts in India.Current scenario of spurious and substandard medicines in India: a systematic review.Collaborative health and enforcement operations on the quality of antimalarials and antibiotics in southeast Asia.It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North-South collaborative trials.The diagnostic accuracy of the hand-held Raman spectrometer for the identification of anti-malarial drugs.Ethical challenges in designing and conducting medicine quality surveys.Substandard and counterfeit medicines: a systematic review of the literature.Assessment of physical premises of selected pharmacies of Nepal.Access to medicines from a health system perspective.Health policy and systems research in access to medicines: a prioritized agenda for low- and middle-income countriesFalsified antimalarials: a minireview.Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.A link between poor quality antimalarials and malaria drug resistance?Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa.The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians.Mapping actions to improve access to medicines for mental disorders in low and middle income countries.The Quality of Medicines Used in Children and Supplied by Private Pharmaceutical Wholesalers in Kinshasa, Democratic Republic of Congo: A Prospective Survey.[Fake drugs, what are we talking about? Counterfeit drugs, informal market, quality of pharmaceutical… Thought from an anthropological study led in Benin].The Belgian commitment to pharmaceutical quality: a model policy to improve quality assurance of medicines available through humanitarian and development programs.Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries.Antibiotic stewardship for drug resistant tuberculosisQuality of medicines in resource-limited settings: need for ethical guidanceTriboelectric Nanogenerator (TENG) Mass Spectrometry of Falsified AntimalarialsQuality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections
P2860
Q27010468-4E021553-31B5-442C-8AB0-A5945BC5C487Q27693421-301EDE24-B6D5-4FB3-B8AA-B558B4C2F446Q28483975-66699F28-2EB9-447E-B7B3-8509B15F9A98Q28538040-8640A59E-BCD3-4BFD-861E-CE06FA880A73Q28538830-2EB15CC6-4DA5-4347-97BA-9074BCB849A2Q28541540-6399D69F-E39B-44AC-B7F5-EAB0F80A3BFAQ28544869-237123F2-24A3-41E6-B2E6-4EE4D7157FD0Q28547513-1BFCB4B3-A547-4C7A-A3E6-DB97ED37CF5BQ28647142-F2EE7E8E-D033-479F-B921-8D2433D10AC1Q30373989-957CB644-9DD2-40FE-9121-93FB05DB3337Q30486867-B6E51691-BD81-474B-A0E0-41631C5EA398Q33667503-66697286-82F6-4A1E-BCFB-8250A7CC9818Q33699168-B8FC4BFC-67B9-45E5-A1C2-B3A0762220CCQ33801472-37ADFD6F-D620-4364-A87A-32402D8F4A68Q34558528-CE049D6F-11A7-43BA-BA14-5840DB7FF303Q35166222-A280E270-ED27-4485-8B75-1C7EEF24E8ECQ35610549-B982F58A-E8EA-4920-8188-6258B373C193Q36394552-492E382E-375B-46DF-B35D-8CF7F08665C4Q36686951-38DDC367-3ABC-4496-A1DF-CCFBF0E4EAC2Q37020706-2B45C602-968D-4FE4-A218-D014BDD14BE5Q37117268-48A7312A-53E0-47CB-9C1E-30DAA4C9BD26Q37221875-C3F108D5-9778-4581-AB9E-846FFCAEC33FQ37224408-1034787B-4480-42ED-80E9-5DC6203C5EB4Q37370574-373B7462-5CFA-4E86-BD4E-A74A007A09FFQ38356412-3280045F-527B-49BF-9997-0FA03C3C477EQ38867438-57DF6A45-FC52-47C0-A928-3ED281878F43Q38994263-0E8BF109-51C3-45EC-A988-0D63A2A351E4Q39300954-7EB908D7-8C93-4369-9598-261114F4F855Q39393283-80E70230-4125-49FD-B1E6-59D8C9EAD20BQ40322708-C1FA06DD-B28F-4713-8BB7-310234C5590DQ47834046-7D75974D-83E3-4160-973B-9548F4EC7A34Q48521945-4D45D666-53B5-472A-8739-53E0934F7E18Q54106036-57252152-9617-47D2-AE01-13C8110A7EE8Q55018359-B8DF77DA-A9F2-4463-9526-33E98D0ABCCDQ55422283-FDA0CA42-BA9A-44D1-A56E-046848CEAC51Q56927264-FC341712-76D8-4D3C-B0D3-5B3DCFC34B2AQ58657032-68BDCCE2-153B-49FF-8367-DC1F951D2E13Q58784635-F49FE0E9-2EEC-4477-9ED1-3DDEE2DAB83DQ58796183-526F9EFF-A330-4E14-8030-8C374352C619
P2860
The primacy of public health considerations in defining poor quality medicines
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The primacy of public health considerations in defining poor quality medicines
@ast
The primacy of public health considerations in defining poor quality medicines
@en
The primacy of public health considerations in defining poor quality medicines
@en-gb
The primacy of public health considerations in defining poor quality medicines
@nl
type
label
The primacy of public health considerations in defining poor quality medicines
@ast
The primacy of public health considerations in defining poor quality medicines
@en
The primacy of public health considerations in defining poor quality medicines
@en-gb
The primacy of public health considerations in defining poor quality medicines
@nl
altLabel
The Primacy of Public Health Considerations in Defining Poor Quality Medicines
@en
prefLabel
The primacy of public health considerations in defining poor quality medicines
@ast
The primacy of public health considerations in defining poor quality medicines
@en
The primacy of public health considerations in defining poor quality medicines
@en-gb
The primacy of public health considerations in defining poor quality medicines
@nl
P2093
P2860
P50
P3181
P1433
P1476
The primacy of public health considerations in defining poor quality medicines
@en
P2093
Abdinasir A Amin
Graham Dukes
Paul N Newton
Phillip Passmore
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001139
P407
P577
2011-12-01T00:00:00Z